Last reviewed · How we verify
Rivaroxaban or Warfarin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Rivaroxaban or Warfarin (Rivaroxaban or Warfarin) — Fujita Health University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rivaroxaban or Warfarin TARGET | Rivaroxaban or Warfarin | Fujita Health University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rivaroxaban or Warfarin CI watch — RSS
- Rivaroxaban or Warfarin CI watch — Atom
- Rivaroxaban or Warfarin CI watch — JSON
- Rivaroxaban or Warfarin alone — RSS
Cite this brief
Drug Landscape (2026). Rivaroxaban or Warfarin — Competitive Intelligence Brief. https://druglandscape.com/ci/rivaroxaban-or-warfarin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab